Table 4.
Selected clinical trials that incorporate bispecific antibodies in experimental therapy of NHL.
| Drug Combination | Target Antigens | Mode of Action of the Combination Agent(s) Other Than Bispecific Antibody | Study Phase | Disease Status | Estimated Study Completion Date | ClinicalTrials.gov Identifier (Other Identifier) |
|---|---|---|---|---|---|---|
| REGN1979 (odronextamab) | CD20/CD3 | 1 | R/R B-NHL | August 2026 | NCT03888105 | |
| REGN1979 (odronextamab) | CD20/CD3 | 1 | R/R B-NHL and CLL | April 2025 | NCT02290951 | |
| AFM13 + NK cells | CD30/CD16A | modified umbilical cord blood immune cells (natural killer [NK] cells) | 1 | R/R Hodgkin and CD30+ B-NHL | April 2023 | NCT04074746 |
| AFM13 | CD30/CD16A | 2 | R/R T-NHL and tMF | February 2023 | NCT04101331 | |
| JNJ-75348780 | CD22/CD3 | 1 | R/R MCL | May 2023 | NCT04540796 | |
| TG-1801 + ublituximab | CD19/CD47 | chimeric anti-CD20 mAb | 1 | R/R B-NHL | August 2021 | NCT03804996 |
| RO7227166 + obinutuzumab + glofitamab | CD19/4-1BB | glycoengineered anti-CD20 antibody obinutuzumab, anti-CD3/CD20 bispecific antibody glofitamab | 1 | R/R B-NHL | January 2023 | NCT04077723 |
Abbreviations: CLL= chronic lymphocytic leukemia; R/R= relapsed/refractory; B-NHL= B cell non-Hodgkin lymphomas; MCL= mantle cell lymphoma; tMF= transformed mycosis fungoides.